ALK-Abelló, Inc.

ALK Abelló Summary Analysis

Established in 1923, ALK Abelló is a leading global pharmaceutical firm specializing in the prevention, diagnosis, and treatment of allergies. The company is dedicated to developing drugs that target the root causes of allergies with a focus on enhancing the quality of life for allergy sufferers.

As the world leader in allergy immunotherapy, ALK offers a range of products including injections, sublingual drops, and the latest innovation – sublingual tablets. These tablets, known for their effectiveness and convenience for patients, aim to stimulate a protective immune response, leading to a long-term reduction in allergy symptoms and reducing the risk of asthma development.

On an annual basis, ALK invests approximately 20% of its revenue in research to advance evidence-based allergy immunotherapies. The company's development pipeline includes sublingual allergy immunotherapy tablets targeting various allergies such as ragweed, house dust mite, and tree pollen. Notably, ALK's strategic partnerships with Merck and Torii Pharmaceutical are intended to drive the development, registration, and commercialization of these tablets in North America and Japan.

With around 1,800 employees, ALK Abelló has a strong global presence, leveraging its subsidiaries, production facilities, and distributors. The company's headquarters are based in Denmark, and it is listed on NASDAQ OMX Copenhagen (OMX: ALK B). In 2013, ALK reported a turnover exceeding DKK 2.2 billion (EURm 300).

Overall, ALK Abelló is poised for continued growth and innovation in the biotechnology, healthcare, and pharmaceutical industries, making it an attractive prospect for potential investors seeking opportunities in the allergy treatment market.